title: Delayed response and survival from NovoTTF-100A in recurrent GBM.
abstract: We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.
authors.affiliation: Department of Medicine, University of Illinois Medical Center, Chicago, IL, USA. jlvillano@uky.edu
authors.forename: J Lee
authors.initials: JL
authors.lastname: Villano
authors.forename: Leena E
authors.initials: LE
authors.lastname: Williams
authors.forename: Karriem S
authors.initials: KS
authors.lastname: Watson
authors.forename: Nandini
authors.initials: N
authors.lastname: Ignatius
authors.forename: Marquess T
authors.initials: MT
authors.lastname: Wilson
authors.forename: Tibor
authors.initials: T
authors.lastname: Valyi-Nagy
authors.forename: Edward A
authors.initials: EA
authors.lastname: Michals
authors.forename: Herbert H
authors.initials: HH
authors.lastname: Engelhard
mesh_terms: D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D004599:Electric Stimulation Therapy / Q000379:methods*; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*